Fredun Pharmaceuticals Limited conducted analyst and institutional investor meetings on March 25, 2026, in compliance with SEBI listing regulations. The pharmaceutical company engaged with a diverse group of investment professionals and high net worth individuals through a structured virtual meeting format.

Meeting Structure and Participation

The company organized a single comprehensive session lasting 40 minutes, from 12:00 PM to 12:40 PM, conducted via Zoom. A total of 38 participants joined the meeting, representing a broad spectrum of the investment community.

Institutional Participation

The meeting attracted representatives from 24 prominent investment organizations, demonstrating significant institutional interest in the company. Key participating firms included:

• Asset Management Companies: Cognizant Capital, A.J. Capital, Allbridge Capital, Dhyana Capital, Helios Capital
• Investment Firms: Tiger Assets, Fyers Assets, PI Square Investments, BlueOcean Asset Management, Alpha AMC
• Research and Advisory: 9 Rays EquiReseach, Lorvet Consultancy, Blue Banyan Advisors
• Venture Capital: Samdareeya Capital Ventures, Ninedot Ventures, Greengen Capital Partners
• Other Financial Services: SmartSync Services, Navrathan & Co., BK Securities

High Net Worth Individual Engagement

The meeting also included 14 high net worth individuals (HNIs), reflecting retail investor interest in the pharmaceutical company. This diverse participation base indicates broad market attention across both institutional and individual investor segments.

Meeting Outcomes and Compliance

The management team provided participants with comprehensive insights into the company's operations while maintaining strict regulatory compliance. Key discussion areas included:

• Business Operations Overview: Management shared details about current business activities and operational performance
• Industry Outlook: Discussions covered the pharmaceutical sector's prospects and market dynamics
• Growth Strategy: The company outlined its strategic initiatives and expansion plans

Importantly, the company ensured all discussions remained within the bounds of publicly available information, with no unpublished price sensitive information (UPSI) shared during the session.

Regulatory Compliance

This disclosure was made pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously intimated about these meetings on March 21, 2026, demonstrating proactive compliance with regulatory requirements. The structured approach to investor engagement reflects the company's commitment to transparency and regulatory adherence in its stakeholder communications.

Fredun Pharmaceuticals Limited has rescheduled its investor meeting, now set for March 25, 2026 at 12:00 PM via virtual platform. The company has formally notified BSE Limited about this updated meeting schedule in compliance with regulatory requirements under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Updated Meeting Details

The rescheduled investor/analyst meeting has been organized with the following specifications:

Regulatory Compliance

The company informed BSE Limited about this rescheduled investor/analyst meeting pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The official communication was digitally signed and dated March 21, 2026, providing advance notice of the updated meeting schedule.

Management Participation

The meeting will involve the management of Fredun Pharmaceuticals Limited engaging with a group of investors and analysts. Managing Director Fredun Nariman Medhora, holding DIN 01745348, has digitally signed the official communication to BSE Limited regarding this rescheduled investor engagement activity.

Virtual Format Adoption

The company has transitioned from the previously planned physical meeting in Mumbai to a virtual format, reflecting modern investor engagement practices. This change allows broader participation from investors and analysts without geographical constraints.

Investor Engagement Commitment

This rescheduled investor/analyst meeting represents Fredun Pharmaceuticals Limited's continued commitment to maintaining transparent communication with its investor community and ensuring regular engagement on business developments and financial progress through accessible virtual platforms.